Patient Trials

Current Trials - still recruiting

- AT UNIVERSITY HOSPITAL SOUTHAMPTON

EME-TIPAC

What is being tested?
Co-trimoxazole, a broad spectrum antibiotic which previous research has shown may improve quality of life and reduce hospital admission in patients with IPF.

Who is it for?
Patients with IPF that is moderate to severe (FVC < 75%). Patients can already be on other treatment (nintedanib/pirfenidone)

What does it involve?
12 – 42 months with hospital visits at 6 weeks, 3 months, 6 months, 9  months and then every 6 months

IPF – JES

What is being tested?
Occupational exposure to asbestos in patients with IPF. Absestos-ILD (asbestosis) can look similar to IPF and this study will investigate if a proportion of IPF is actually caused by occupational exposure to asbestos.

Who is it for?
All patients with IPF (even those already on other studies)

What does it involve?
A blood test (to look for genetic features which might relate to asbestos exposure) and a telephone interview

trials coming to southampton soon

Celegene

What is being tested?
CC-90001, an experimental drug which may stop a protein that is thought to be involved in the IPF process.

Who is it for?
Patients with IPF not currently on anti-fibrotic treatment, who have mild to moderate IPF (based on lung function – Forced Vital Capacity >45% and DLCO 30-85%)

What does it involve?
Randomised to drug or placebo and treated initially for 24 weeks and then possibly another 28 weeks. Between 9 and 15 hospital visits. Blood tests, lung function and CT scan.

TRAIL1

What is being tested?
Pirfenidone, an anti-fibrotic drug used to treat patients with IPF

Who is it for?
Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease (RAILD). RAILD has many similar characteristics to IPF and this study will see if pirfenidone is effective in RAILD.

What does it involve? Randomised to drug versus placebo. 12 months of treatment involving 8 hospital visits, lung function a CT scan and blood tests

For more info please email  [email protected]  or [email protected]